Newer agents for the treatment of painful diabetic peripheral neuropathy

被引：7

作者：

Freeman R. ^{[1
]}

机构：

[1] Autonomic and Peripheral Nerve Laboratory, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA 02215

来源：

Current Diabetes Reports | 2005年 / 5卷 / 6期

关键词：

Neuropathic Pain; Gabapentin; Tramadol; Venlafaxine; Memantine;

D O I：

10.1007/s11892-005-0047-7

中图分类号：

学科分类号：

摘要：

Neuropathic pain is responsible for a significant amount of the morbidity associated with generalized and focal peripheral neuropathies in diabetes. It is a consequence of alterations in neuronal function, chemistry, and structure that occur secondary to nerve injury. A variety of agents from diverse pharmacologic classes, the so-called adjuvant analgesics, have been used to treat neuropathic pain. These include antidepressants, first- and second-generation anticonvulsants, antiarrhythmic agents, topical agents, N-methyl-D-aspartate receptor antagonists, and the opioid analgesics. The availability of several newer agents, used alone or in combination, has resulted in the successful alleviation of neuropathic pain in many patients. Recent advances in the understanding of pain mechanisms at multiple central nervous system levels should pave the way toward more effective treatment modalities with less prominent side effects. Copyright © 2005 by Current Science Inc.

引用

页码：409 / 416

页数：7

共 98 条

[1] Wild S., Roglic G., Green A., Et al., Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030, Diabetes Care, 27, pp. 1047-1053, (2004)
[2] Ziegler D., Gries F.A., Spuler M., Lessmann F., The epidemiology of diabetic neuropathy, J Diabetes Complications, 6, pp. 49-57, (1992)
[3] Schmader K.E., Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy, Clin J Pain, 18, pp. 350-354, (2002)
[4] Partanen J., Niskanen L., Lehtinen J., Et al., Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus, N Engl J Med, 333, pp. 89-94, (1995)
[5] Galer B.S., Gianas A., Jensen M.P., Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life, Diabetes Res Clin Pract, 47, pp. 123-128, (2000)
[6] Basbaum A.I., Jessell T.M., The perception of pain, Principles of Neural Science, pp. 472-491, (2000)
[7] Woolf C.J., Mannion R.J., Neuropathic pain: Aetiology, symptoms, mechanisms, and management, Lancet, 353, pp. 1959-1964, (1999)
[8] Max M.B., Culnane M., Schafer S.C., Et al., Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood, Neurology, 37, pp. 589-596, (1987)
[9] Max M.B., Kishore-Kumar R., Schafer S.C., Et al., Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial, Pain, 45, pp. 3-9, (1991)
[10] Max M.B., Lynch S.A., Muir J., Et al., Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy, N Engl J Med, 326, pp. 1250-1256, (1992)

← 1 2 3 4 5 6 7 8 9 10 →